Home Healthcare Pharmaceuticals Crohn's Disease Therapeutics Market

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (TNF-Alpha inhibitors, 5-Aminosalicylates, Others), By Gender Type (Men, Women), By Disease Type (Small/Large Intestinal Type, Large Intestinal Type, Small Intestinal Type), By Age Group (49 yrs. and below, 50 yrs. and above) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR3417DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Crohn's Disease Therapeutics Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. TNF-Alpha inhibitors
    2. 5-Aminosalicylates
    3. Others
  2. Crohn's Disease Therapeutics Market, By Gender Type 2022-2034 (USD MILLION/ Units)
    1. Men
    2. Women
  3. Crohn's Disease Therapeutics Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Small/Large Intestinal Type
    2. Large Intestinal Type
    3. Small Intestinal Type
  4. Crohn's Disease Therapeutics Market, By Age Group 2022-2034 (USD MILLION/ Units)
    1. 49 yrs. and below
    2. 50 yrs. and above
  5. Regional Crohn's Disease Therapeutics Market
    1. North America
      1. North America Crohn's Disease Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
      2. North America Crohn's Disease Therapeutics Market By Gender Type 2022-2034 (USD MILLION/ Units)
        1. Men
        2. Women
      3. North America Crohn's Disease Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Small/Large Intestinal Type
        2. Large Intestinal Type
        3. Small Intestinal Type
      4. North America Crohn's Disease Therapeutics Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. 49 yrs. and below
        2. 50 yrs. and above
      5. U.S.
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      6. Canada
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
    2. Europe
      1. Europe Crohn's Disease Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
      2. Europe Crohn's Disease Therapeutics Market By Gender Type 2022-2034 (USD MILLION/ Units)
        1. Men
        2. Women
      3. Europe Crohn's Disease Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Small/Large Intestinal Type
        2. Large Intestinal Type
        3. Small Intestinal Type
      4. Europe Crohn's Disease Therapeutics Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. 49 yrs. and below
        2. 50 yrs. and above
      5. U.K.
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      6. Germany
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      7. France
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      8. Spain
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      9. Italy
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      10. Russia
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      11. Nordic
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      12. Benelux
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      13. Rest of Europe
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
    3. APAC
      1. APAC Crohn's Disease Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
      2. APAC Crohn's Disease Therapeutics Market By Gender Type 2022-2034 (USD MILLION/ Units)
        1. Men
        2. Women
      3. APAC Crohn's Disease Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Small/Large Intestinal Type
        2. Large Intestinal Type
        3. Small Intestinal Type
      4. APAC Crohn's Disease Therapeutics Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. 49 yrs. and below
        2. 50 yrs. and above
      5. China
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      6. Korea
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      7. Japan
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      8. India
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      9. Australia
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      10. Singapore
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      11. Taiwan
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      12. South East Asia
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      13. Rest of Asia-Pacific
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
    4. Middle East and Africa
      1. Middle East and Africa Crohn's Disease Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
      2. Middle East and Africa Crohn's Disease Therapeutics Market By Gender Type 2022-2034 (USD MILLION/ Units)
        1. Men
        2. Women
      3. Middle East and Africa Crohn's Disease Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Small/Large Intestinal Type
        2. Large Intestinal Type
        3. Small Intestinal Type
      4. Middle East and Africa Crohn's Disease Therapeutics Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. 49 yrs. and below
        2. 50 yrs. and above
      5. UAE
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      6. Turkey
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      7. Saudi Arabia
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      8. South Africa
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      9. Egypt
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      10. Nigeria
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      11. Rest of MEA
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
    5. LATAM
      1. LATAM Crohn's Disease Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
      2. LATAM Crohn's Disease Therapeutics Market By Gender Type 2022-2034 (USD MILLION/ Units)
        1. Men
        2. Women
      3. LATAM Crohn's Disease Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Small/Large Intestinal Type
        2. Large Intestinal Type
        3. Small Intestinal Type
      4. LATAM Crohn's Disease Therapeutics Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. 49 yrs. and below
        2. 50 yrs. and above
      5. Brazil
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      6. Mexico
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      7. Argentina
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      8. Chile
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      9. Colombia
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
      10. Rest of LATAM
        1. TNF-Alpha inhibitors
        2. 5-Aminosalicylates
        3. Others
        4. Men
        5. Women
        6. Small/Large Intestinal Type
        7. Large Intestinal Type
        8. Small Intestinal Type
        9. 49 yrs. and below
        10. 50 yrs. and above
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.